WO1998056370A3 - Therapeutic nanospheres - Google Patents

Therapeutic nanospheres Download PDF

Info

Publication number
WO1998056370A3
WO1998056370A3 PCT/US1998/011880 US9811880W WO9856370A3 WO 1998056370 A3 WO1998056370 A3 WO 1998056370A3 US 9811880 W US9811880 W US 9811880W WO 9856370 A3 WO9856370 A3 WO 9856370A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenylbutyrate
drugs
appears
formulations
nanospheres
Prior art date
Application number
PCT/US1998/011880
Other languages
French (fr)
Other versions
WO1998056370A2 (en
Inventor
Scott Walsh
Ronald Rubenstein
Pamela Zeitlin
Kam Leong
Original Assignee
Univ Johns Hopkins Med
Scott Walsh
Ronald Rubenstein
Pamela Zeitlin
Kam Leong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Scott Walsh, Ronald Rubenstein, Pamela Zeitlin, Kam Leong filed Critical Univ Johns Hopkins Med
Priority to CA002303268A priority Critical patent/CA2303268A1/en
Priority to JP50306999A priority patent/JP2002506436A/en
Priority to EP98928941A priority patent/EP0989849A2/en
Priority to AU80624/98A priority patent/AU749032B2/en
Publication of WO1998056370A2 publication Critical patent/WO1998056370A2/en
Publication of WO1998056370A3 publication Critical patent/WO1998056370A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/882—Assembling of separate components, e.g. by attaching
    • Y10S977/884—Assembled via biorecognition entity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture

Abstract

4-Phenylbutyrate exerts many beneficial biological effects. It appears to induce the transcription of certain promoters, as well as having a remedial effect on proteins which are aberrantly localized within the cell. In addition, it appears to cause cells to developmentally differentiate. The present invention provides nanosphere formulations of 4-phenylbutyrate and other drugs which remediate defective protein localization intracellularly. These formulations permit lower concentrations of drugs to be administered, providing both cost and safety benefits.
PCT/US1998/011880 1997-06-13 1998-06-11 Therapeutic nanospheres WO1998056370A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002303268A CA2303268A1 (en) 1997-06-13 1998-06-11 Therapeutic nanospheres
JP50306999A JP2002506436A (en) 1997-06-13 1998-06-11 Therapeutic nanospheres
EP98928941A EP0989849A2 (en) 1997-06-13 1998-06-11 Therapeutic nanospheres
AU80624/98A AU749032B2 (en) 1997-06-13 1998-06-11 Therapeutic nanospheres

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4949797P 1997-06-13 1997-06-13
US60/049,497 1997-06-13

Publications (2)

Publication Number Publication Date
WO1998056370A2 WO1998056370A2 (en) 1998-12-17
WO1998056370A3 true WO1998056370A3 (en) 1999-04-01

Family

ID=21960137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/011880 WO1998056370A2 (en) 1997-06-13 1998-06-11 Therapeutic nanospheres

Country Status (6)

Country Link
US (1) US6207195B1 (en)
EP (1) EP0989849A2 (en)
JP (1) JP2002506436A (en)
AU (1) AU749032B2 (en)
CA (1) CA2303268A1 (en)
WO (1) WO1998056370A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242172B2 (en) 1998-02-11 2012-08-14 Trustees Of Boston University 2,2-dimethylbutyric acid oral pharmaceutical compositions
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
US8993581B2 (en) 2009-09-24 2015-03-31 Trustees Of Boston University Methods for treating viral disorders

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US7375096B1 (en) * 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
CA2409093C (en) 2000-05-16 2009-07-21 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
EP1291015A1 (en) * 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US8178128B2 (en) * 2001-12-05 2012-05-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles containing polymeric nucleic acid homologs
DE60324225D1 (en) * 2002-06-14 2008-12-04 Rohm & Haas Colorants, dispersants and dispersions containing polymeric nanoparticles
US20040058457A1 (en) * 2002-08-29 2004-03-25 Xueying Huang Functionalized nanoparticles
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US20050084513A1 (en) * 2003-10-21 2005-04-21 Board Of Regents Nanocoating for improving biocompatibility of medical implants
DE102004011776A1 (en) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Carrier system in the form of protein-based nanoparticles for the cell-specific accumulation of pharmaceutically active substances
WO2006023207A2 (en) * 2004-08-19 2006-03-02 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents
JP2008511611A (en) * 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド Therapeutic 4-phenylbutyric acid controlled release formulation
US20090311767A1 (en) * 2005-04-21 2009-12-17 Chiles Thomas C Method for molecular delivery into cells using naonotube spearing
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
KR20080063408A (en) * 2005-10-18 2008-07-03 신벤션 아게 Thermoset particles and methods for production thereof
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业（深圳）有限公司 CO2 laser welding apparatus
EP1988941A2 (en) * 2006-01-31 2008-11-12 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) * 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US20100143373A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Methods of treating systemic lupus erythematosus
US9040816B2 (en) * 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
EP2076590A4 (en) 2007-05-03 2011-06-01 Medimmune Llc Auto-antibody markers of autoimmune disease
CN102781237A (en) * 2009-11-23 2012-11-14 天蓝制药公司 Cyclodextrin-based polymers for therapeutic delivery
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
US9173971B2 (en) * 2010-11-12 2015-11-03 University Of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
EP2599481A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment or prevention of various diseases
EP2599482A1 (en) 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
EP2970440B1 (en) 2013-03-14 2019-11-20 University of Notre Dame du Lac Selective uv crosslinking of peptides and functional moieties to immunoglobulins
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
CA3061950A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
KR20200141986A (en) 2018-02-12 2020-12-21 다이어비티스-프리, 인크. Improved antagonistic anti-human CD40 monoclonal antibody
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
WO2020139874A1 (en) * 2018-12-27 2020-07-02 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
CA3142142A1 (en) 2019-05-31 2020-12-03 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
KR20220083773A (en) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. Improved LAMP Constructs Containing Cancer Antigens
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004671A1 (en) * 1992-08-26 1994-03-03 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
WO1996029998A1 (en) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
WO1997046588A1 (en) * 1996-06-04 1997-12-11 The Regents Of The University Of California Cellular internalization of pigr stalk and associated ligands

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004671A1 (en) * 1992-08-26 1994-03-03 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
WO1996029998A1 (en) * 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
WO1997046588A1 (en) * 1996-06-04 1997-12-11 The Regents Of The University Of California Cellular internalization of pigr stalk and associated ligands

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GALLET X ET AL: "PREDICTION OF THE ANTIGENIC SITES OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN BY MOLECULAR MODELLING", PROTEIN ENGINEERING, vol. 8, no. 8, 1 August 1995 (1995-08-01), pages 829 - 834, XP000565688 *
KO Y H ET AL: "THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OVEREXPRESSION, PURIFICATION, AND CHARACTERIZATION OF WILD TYPE ANDDELTAF508 MUTANT FORMS OF THE FIRST NUCLEOTIDE BINDING FOLD IN FUSION WITH THE MALTOSE-BINDING PROTEIN", J. BIOL. CHEM., vol. 268, no. 32, 15 November 1993 (1993-11-15), pages 24330 - 24338, XP002055212 *
MAO H -Q ET AL: "DNA-CHITOSAN NANOSPHERES FOR GENE DELIVERY", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, 7 July 1996 (1996-07-07), pages 401/402, XP002052414 *
NEWMARK H L ET AL: "BUTYRATE AS A DIFFERENTIATING AGENT: PHARMACOKINETICS, ANALOGUES AND CURRENT STATUS", CANCER LETTERS, vol. 78, 1994, pages 1 - 5, XP000615955 *
RUBENSTEIN, R.C., ET AL.: "In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta.F508-CFTR", J. CLIN. INVEST., vol. 100, no. 10, 15 November 1997 (1997-11-15), pages 2457 - 2465, XP002076381 *
TRUONG V L ET AL: "A TARGET-SPECIFIC MICROSPHERES DRUG DELIVERY SYSTEM MADE OF ENZYMATICALLY DEGRADEABLE GELATIN AND CHONDROITIN SULFATE COACERVATES", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, vol. 20, 25 July 1993 (1993-07-25), pages 474/475, XP002016479 *
WALSH S M ET AL: "COMBINATION OF DRUG AND GENE DELIVERY BY GELATIN NANOSPHERES FOR THE TREATMENT OF CYSTIC FIBROSIS", PROCEEDINGS OF THE 24TH. INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE OF BIOACTIVE MATERIALS, STOCKHOLM, JUNE 15 - 19, 1997, no. SYMP. 24, 15 June 1997 (1997-06-15), CONTROLLED RELEASE SOCIETY, pages 75/76, XP002052415 *
ZABNER J ET AL: "REPEAT ADMINISTRATION OF AN DENOVIRUS VECTOR ENCODING CYSTIC FIBROSIS TRANSMEMBRANCE CONDUCTANCE REGULATOR TO THE NASAL EPITHELIUM OF PATIENTS WITH CYSTIC FIBROSIS", JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 6, 15 March 1996 (1996-03-15), pages 1504 - 1511, XP000575871 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242172B2 (en) 1998-02-11 2012-08-14 Trustees Of Boston University 2,2-dimethylbutyric acid oral pharmaceutical compositions
US8993581B2 (en) 2009-09-24 2015-03-31 Trustees Of Boston University Methods for treating viral disorders
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders

Also Published As

Publication number Publication date
JP2002506436A (en) 2002-02-26
AU749032B2 (en) 2002-06-20
US6207195B1 (en) 2001-03-27
EP0989849A2 (en) 2000-04-05
CA2303268A1 (en) 1998-12-17
WO1998056370A2 (en) 1998-12-17
AU8062498A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
WO1998056370A3 (en) Therapeutic nanospheres
EP1420009A3 (en) Novel amino acid derivatives with improved multi-drug resistance activity
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MX9703621A (en) Novel amino acid derivatives with improved multi-drug resistance activity.
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
DK1289517T3 (en) Pharmaceutical compositions containing cannabidiol derivatives
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
BRPI0113477B8 (en) fusion protein for delivering a peptide, protein, glycoprotein or oligonucleotide into a cell
DE69822496D1 (en) LIPID COMPLEX LYOPHILISATE OF WATER-INSOLUBLE PORPHYRINE
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
ATE226065T1 (en) SOLID INSTANT-RELEASE DOSAGE FORMS AND METHOD FOR THE PRODUCTION THEREOF
Gajecka et al. The protective effect of vitamins C and E against B (a) P-induced genotoxicity in human lymphocytes
WO2000023587A3 (en) Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
WO1999045103A3 (en) Human spinal cord cell lines and methods of use therefor
WO2004059002A3 (en) Method for determining the homeostasis of hairy skin
WO2004050010A3 (en) Composition, especially a cosmetic composition, containing at least one alkyl para-hydroxybenzoate and at least one lipophilic amino acid derivative
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2303268

Country of ref document: CA

Ref country code: CA

Ref document number: 2303268

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 80624/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998928941

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998928941

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 80624/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998928941

Country of ref document: EP